A two-photon fluorescent probe sensitive to NADPH reveals metabolic aberrations in brain cells arising from mitochondrial dysfunction in Alzheimer’s disease

Mitochondrial dysfunction is implicated in the pathogenesis of numerous neurodegenerative disorders, including Alzheimer's disease (AD). Nicotinamide adenine dinucleotide phosphate (NADPH) plays a crucial cofactor as a cofactor in diverse biological processes, with the interconversion between NADP+ and NADPH serving a pivotal function in intracellular reductive metabolism and redox homeostasis. Herein, we present a fast, ultrasensitive, two-photon fluorescent probe (NATP-3) with large Stokes3 shifts for real-time detection of NADPH levels in mitochondria of the brain cells and elucidate mitochondrial damage in AD. Significantly reduced levels of NAD(P)H in living brain cells under Aβ stress or in AD model animals such as C. elegans were intuitively observed, suggesting that cellular mitochondrial dysfunction and metabolic disorders in the brain are closely related to AD. Importantly, utilizing a high-throughput screening platform based on NATP-3, we identified apigenin as a promising candidate for mitigating mitochondrial dysfunction in AD. Notably, apigenin reinstates mitochondrial NAD(P)H production, thereby providing a potential entity molecule for intervening in mitochondrial damage during AD. This work provides a valuable tool for detecting and intervening in mitochondrial function and metabolic homeostasis associated with AD processes, emphasizing the importance of understanding the molecular mechanisms of mitochondrial dysfunction associated with neurodegenerative diseases.